Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

2.290 -0.060 (-2.55%)
Streaming Delayed Price Updated: 3:48 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu Biopharma Inc

< Previous 1 2 3 Next >
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Via ACCESSWIRE
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Via ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Via ACCESSWIRE
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
Via ACCESSWIRE
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
Via ACCESSWIRE
Aytu BioPharma Inc. (NASDAQ: AYTU) Near the Top of Equities by Percentage Gain on 9/28
Via Investor Brand Network
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Via ACCESSWIRE
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
Via ACCESSWIRE
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
Via ACCESSWIRE
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
Via ACCESSWIRE
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
Via ACCESSWIRE
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
Via ACCESSWIRE
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Via ACCESSWIRE
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Via ACCESSWIRE
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Via ACCESSWIRE
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
Via ACCESSWIRE
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
Via ACCESSWIRE
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
Via ACCESSWIRE
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Via ACCESSWIRE
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Via ACCESSWIRE
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.